In response to public concern, and federal inquiry, stemming from myriad current events involving the oversight of the products it regulates, the FDA has recently developed and issued new regulations, guidance, and procedures to support the agency’s mission to improve the conduct of clinical trials, assess the accuracy and reliability of clinical trial data, and secure the protection of human research participants involved in those trials. This course will address some of the incidents that have led to these new developments, the federal agencies involved in overseeing the FDA, their findings, and how the FDA’s response to the recommendations will impact the conduct of clinical trials.
- Describe causal factors and their relation to the current clinical research environment
- Examine key areas of concern from Congress, the Office of the Inspector General (OIG), and the General Accounting Office (GAO)
- Identify new regulations, guidance, procedures, coalitions, and working groups, and pending and proposed legislation
- Clinical Quality Assurance Professionals
- Clinical Research Associates
- Project Managers
- Clinical Investigators
- Study Coordinators
- IRB Professionals
- Institutional Officials involved in oversight of clinical research
- GCP -Focused Regulatory Affairs Professionals
Elizabeth Ronk Nelson, MPH
Click here for complete trainer biographies
2 hours; 1:00 - 3:00 p.m. Eastern
September 30, 2010
Hold this course at your company!For more information, contact Naila Ganatra at (215) 413-2471